New diabetes clinical trial: Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and Albuminuria

Published on: August 19, 2019 at 07:00PM
Condition:   Type 2 Diabetes With Renal Manifestations
Interventions:   Drug: Semaglutide, 1.34 mg/mL;   Other: Placebo, 1,34 mg/mL;   Drug: Empagliflozin 25 MG
Sponsors:   Steno Diabetes Center Copenhagen;   Novo Nordisk A/S
Not yet recruiting